Skip to NavigationSkip to content

Flynn Pharma

Pfizer successfully appeals 2,600% price hiking case

Pfizer and co-defendant Flynn Pharma have won their appeal against a £90 million fine imposed on them by the Competition and Markets Authority (CAM).

The CAM revealed that it may well choose to appeal the decision, which the Competition Appeal Tribunal found in Pfizer and Flynn’s favour after deciding that they had not abused their dominance of the market.

The particular market was for the treatment of epilepsy and the two companies’ sale of phenytoin sodium capsules.

Pfizer slapped with record £84.2 million fine for 2,600% price increase

Pfizer has been hit with a record fine by The Competition and Markets Authority for the increase in the price of phenytoin sodium capsules, a drug designed to help control symptoms of epilepsy. The CMA has also imposed a £5.2 million fine upon the distribution company, Flynn Pharma.

Pfizer fined for epilepsy drug price increase by UK antitrust regulator

Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and Markets Authority (CMA).

The pharma giant sold the rights to Epanutin in the UK to Flynn Pharma in 2012. The CMA, however, found that that Pfizer increased the price it sold the drug to Flynn at between 8 and 17 times Pfizer’s historic prices of the drug. Flynn were then said to have sold the drug at prices which were between 25 and 27 times higher than those historically charged by Pfizer.

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

Pfizer building
Pfizer is under investigation by the Competition and Markets Authority

Pharma firms Pfizer and Flynn Pharma have been accused by the UK's competition watchdog of charging ‘excessive and unfair’ prices for the anti-epilepsy drug phenytoin.

Phenytoin sodium capsules, manufactured by Pfizer and distributed by Flynn in its generic form, are used by some 50,000 people in Britain.

The Competition and Markets Authority (CMA) says that in its provisional view, both companies “abused a dominant position by charging excessive and unfair prices” that are in breach of UK and EU competition law.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches